Shigehiro Nagasawa

发表

Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/β-catenin signal activation

Y. Ohishi, A. Masumoto, M. Yada, 2022, Oncology letters.

Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib

A. Masumoto, M. Yada, K. Motomura, 2022, Journal of viral hepatitis.

Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatment

A. Masumoto, M. Yada, K. Motomura, 2021, Journal of viral hepatitis.

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma

M. Nakamuta, M. Kohjima, Tsuyoshi Yoshimoto, 2022, Internal medicine.

Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI

A. Masumoto, M. Yada, K. Motomura, 2021, Molecular and clinical oncology.

A case of granulocyte colony-stimulating factor-producing intrahepatic sarcomatoid cholangiocarcinoma

Y. Ohishi, A. Masumoto, M. Yada, 2021, Clinical Journal of Gastroenterology.

Multicentric recurrence of intraductal papillary neoplasm of bile duct after spontaneous detachment of primary tumor: A case report

A. Masumoto, M. Yada, K. Motomura, 2022, World journal of clinical cases.

Combined Ultrasound and Computed Tomography Guidance in Radiofrequency Ablation for Hepatocellular Carcinoma Reduces Local Recurrence Rate.

A. Masumoto, M. Yada, K. Motomura, 2023, Cancer diagnosis & prognosis.